EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

Ulrike Bauer iD, Maria R Troppmair iD, Najib Ben Khaled iD, Julia M Grottenthaler iD, Friedrich Foerster iD, Sena Blümel iD, Sophia Heinrich iD, Friedrich Sinner iD, Matthias Pinter iD, Magdalena Hahn iD, Florian van Bömmel iD, Bernhard Scheiner iD und 11 weitere

Liver International · 2026

DOI: 10.1111/liv.70692 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Ulrike Bauer und 22 weiteren Autor:innen. Beteiligte Einrichtung: TUM School of Medicine and Health-Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Liver Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post‐transplant outcomes across 10 European centres using data from the multinational LITCHI ( Li ver t ransplantation after i mmune c heckpoint i nhibition) registry. Clinical and tumour characteristics, ICI regimens and post‐transplant immunosuppression were assessed, and overall and rejection‐free survival were estimated using the log‐rank test. Among 18 patients who underwent LTx following ICI, 15 were treated with atezolizumab plus bevacizumab. One‐year survival was 77% (95% CI 67.3–87.8) and four rejection episodes occurred, with one fatal case after a 13‐day wash‐out and three non‐fatal episodes, each responsive to escalation of immunosuppression. Overall, however, no intensified immunosuppression was required in our cohort. Despite tumour burden beyond Milan criteria in most patients before ICI initiation, HCC recurrence occurred in only one patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsLiver TransplantationAgedFemaleHumansMaleMiddle AgedEuropeGraft RejectionImmunosuppressive AgentsNeoplasm Recurrence, LocalRegistriesTreatment Outcome

Stichwörter der Autor:innen

HCCICILTxhepatocellular carcinomaimmune checkpoint inhibitionliver transplantationregistry

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • TUM School of Medicine and Health-Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.
  • Department of Internal Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University Innsbruck, Innsbruck, Austria.
  • Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
  • BZKF-Bavarian Center for Cancer Research, Bavaria, Germany.
  • Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectiology and Geriatrics, University Hospital Tuebingen, Tuebingen, Germany.
  • Department of Medicine I, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.

ORCID-Profile: Ulrike Bauer, Maria R Troppmair, Najib Ben Khaled, Julia M Grottenthaler, Friedrich Foerster, Sena Blümel, Sophia Heinrich, Friedrich Sinner, Matthias Pinter, Magdalena Hahn, Florian van Bömmel, Bernhard Scheiner, Marino Venerito, Richard Taubert, Andreas E Kremer, Arndt Weinmann, Enrico N De Toni, Heinz Zoller, Ursula Ehmer

Förderung

  • Roche

Zitieren

APA

Bauer, U., Troppmair, M. R., Khaled, N. B., Grottenthaler, J. M., Foerster, F., Blümel, S., Heinrich, S., Sinner, F., Pinter, M., Hahn, M., van Bömmel, F., Scheiner, B., Venerito, M., Taubert, R., Kremer, A. E., Weinmann, A., Berg, C. P., Lange, C. M., De Toni, E. N., …, & Ehmer, U. (2026). Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry. Liver International. https://doi.org/10.1111/liv.70692

Vancouver

Bauer U, Troppmair MR, Khaled NB, Grottenthaler JM, Foerster F, Blümel S, et al. Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry. Liver International. 2026. doi:10.1111/liv.70692

BibTeX
@article{Bauer2026,
  author = {Bauer, Ulrike and Troppmair, Maria R and Khaled, Najib Ben and Grottenthaler, Julia M and Foerster, Friedrich and Blümel, Sena and Heinrich, Sophia and Sinner, Friedrich and Pinter, Matthias and Hahn, Magdalena and van Bömmel, Florian and Scheiner, Bernhard and Venerito, Marino and Taubert, Richard and Kremer, Andreas E and Weinmann, Arndt and Berg, Christoph P and Lange, Christian M and De Toni, Enrico N and Djanani, Angela and Zoller, Heinz and Schmid, Roland M and Ehmer, Ursula},
  title = {Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70692}
}
Kostenlos starten →